期刊文献+

化学修饰的重组腺相关病毒载体

Chemical Modification of Recombinant Adenovirus-associated Virus Vectors
原文传递
导出
摘要 重组腺相关病毒(Recombinant adenovirus-associated virus,rAAV)载体源于腺相关病毒(Adeno-associated virus,AAV),以其无致病性、低免疫原性、可定点整合及在宿主细胞内长期表达等优势,广泛应用于肿瘤和遗传疾病等基因治疗研究,被视为最有前途的基因治疗载体之一。但是人体内广泛存在AAV中和抗体,以及rAAV对体内特定组织或细胞的靶向性欠理想,限制了其在临床上的应用。经化学修饰的rAAV可以抵御血清中和抗体,提高转导靶向性,还可实现rAAV体内动态监测,这为解决当前rAAV载体的问题提供了新的思路和方法。本文对化学修饰的rAAV展开系统阐述,并对其未来发展趋势作出展望。 Recombinant adenovirus-associated virus (rAAV) vectors mediated gene delivery system has been widely used in the treatments of cancer or other genetic diseases. It is considered to be one of the most promising vector owing to its non-pathogenicicity, low immune response, potential to integrate site-specif- ically, persistent and stable gene expression. However, it was limited in clinical applications because it is easy to be neutralized in serum and non-selection to the target site. Chemical modifications of rAAV have been studied to overcome those problems. This article reviewed the progress of chemical modifications of rAAV by various compounds and different modification methods, and predicted what the researches needed to do in the future.
出处 《病毒学报》 CAS CSCD 北大核心 2013年第5期566-572,共7页 Chinese Journal of Virology
基金 国家自然科学基金资助项目No.30900351 30973591 81271691 福建省自然科学基金资助项目No.2013J01338
关键词 重组腺相关病毒载体 化学修饰 抗血清中和 靶向性 动态监测 Recombinant ad neutralization Targeted D enovirus-associated virus (rAAV) vectors Chemical modification Anti-serum ynamlc monitoring
  • 相关文献

参考文献7

二级参考文献170

  • 1Yi-GangWANG,Jin-HuiWANG,Yan-HongZHANG,QingGU,Xin-YuanLIU.Antitumor Effect of a Novel Adeno-associated Virus Vector Targeting to Telomerase Activity in Tumor Cells[J].Acta Biochimica et Biophysica Sinica,2004,36(7):492-500. 被引量:6
  • 2王志刚.超声微泡造影剂在疾病诊断与治疗中的研究进展[J].中国医学影像技术,2005,21(8):1148-1150. 被引量:46
  • 3潘秋卫,蔡荣,刘新垣,钱程.肿瘤基因治疗新策略——RNA干扰[J].科学通报,2006,51(9):993-997. 被引量:7
  • 4Grifman M, Trepel M, Speece P, et al. Incorporation of tumor-targeting peptides into recombinant adeno-associated virus capsids. Mol Ther, 2001, 3(6): 964--975.
  • 5Yang Q, Mamounas M, Yu G, et al. Development of novel cell surface CD34-targeted recombinant adeno-associated virus vectors for gene therapy. Hum Gene Ther, 1998, 9(13): 1929--1937.
  • 6Wu P, Xiao W, Conlon T, et al. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol, 2000, 74(18): 8635--8647.
  • 7Weichert W S, Parker J S, Wahid A T, et al. Assaying for structural variation in the parvovirus capsid and its role in infection. Virology, 1998, 250(1): 106-117.
  • 8Chapman M S, Rossmann M G. Structure, sequence, and function correlations among parvoviruses. Virology, 1993, 194(2): 491--508.
  • 9Shi W, Arnold G S, Bartlett J S. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther, 2001, 12(14): 1697--1711.
  • 10Shi W, Hemminki A, Bartlett J S. Capsid modifications overcome low heterogeneous expression of heparan sulfate proteoglycan that limits AAV2-mediated gene transfer and therapeutic efficacy in human ovarian carcinoma. Gynecol Oncol, 2006, 103(3): 1054--1062.

共引文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部